Q34 – 36: Liver Toxicity Prophylaxis

!Liver Toxicity Prophylaxis
Liver Toxicity Prophylaxis section can only be completed on the Day 100 and six-month follow-up forms. These questions will be skipped for all subsequent reporting periods.

*Combined Follow-Up and Liver Toxicity Prophylaxis
In scenarios where a cellular therapy was given after an HCT and this form is now being completed based on the subsequent cellular therapy date, these questions still apply and should be answered.

Question 34: Was specific therapy used to prevent liver toxicity?

Liver toxicities in transplant patients may be related to drugs / treatments, infection, GVHD, iron overload, cirrhosis, or sinusoidal obstructive syndrome (SOS) / veno-occlusive disease (VOD). Agents such as ursodiol may be given as prophylaxis against one or more of these transplant-related liver injuries. Agents given to prevent liver toxicity will generally be started prior to or during the conditioning regimen and may be continued well after transplant.

Indicate whether the recipient received any therapy intended to prevent liver toxicity during the current reporting period. For the Day 100 reporting period, this includes any therapy given during the conditioning regimen. Report only agents given to prevent liver toxicities, not those given to treat a diagnosed liver injury or toxicity. If liver toxicity prophylaxis was given, report Yes. If liver toxicity prophylaxis was not given during the reporting period, report No.

Questions 35 – 36: Specify therapy (check all that apply)

Select the agent(s) given during the reporting period to prevent liver toxicity, including therapy given during the conditioning regimen. Only report agents given to prevent liver toxicities, not those given to treat a diagnosed liver injury or toxicity. If Other therapy is reported, specify agent(s).

Section Updates:

Question Number	Date of Change	Add/Remove/Modify	Description	Reasoning (If applicable)
Q34	1/23/2026	Add	Combined Follow Up and Liver Toxicity Prophylaxis blue box added: Combined Follow-Up and Liver Toxicity Prophylaxis: In scenarios where a cellular therapy was given after an HCT and this form is now being completed based on the subsequent cellular therapy date, these questions still apply and should be answered.	Added for clarification

Copyright © 2004-2025 The Medical College of Wisconsin, Inc. and NMDP. All Rights Reserved.
CIBMTR® (Center for International Blood and Marrow Transplant Research) is a research collaboration between the Medical College of Wisconsin and NMDP.